Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENTR 601 44

Drug Profile

ENTR 601 44

Alternative Names: ENTR-601-44; Exon 44 Skipping Oligonucleotide - Entrada Therapeutics

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Entrada Therapeutics
  • Class Drug conjugates; Oligonucleotides
  • Mechanism of Action Nucleic acid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Duchenne muscular dystrophy

Most Recent Events

  • 13 Mar 2024 Entrada Therapeutics announces intention to submit a regulatory application for a phase II trial in Duchenne muscular dystrophy in the fourth quarter of 2024
  • 08 Aug 2023 Phase-I clinical trials in Duchenne muscular dystrophy (In volunteers) in United Kingdom (IV)
  • 08 Aug 2023 Entrada Therapeutics plans a global multiple ascending dose trial in Duchenne muscular dystrophy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top